Triclabendazole

Triclabendazole
Clinical data
Trade namesFasinex, Egaten, others
AHFS/Drugs.comMonograph
MedlinePlusa619048
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismOxidation to sulfone and sulfoxide metabolites
Elimination half-life22–24 hours
ExcretionFeces (>95%), urine (2%), milk (<1%)
Identifiers
  • 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.127.414 Edit this at Wikidata
Chemical and physical data
FormulaC14H9Cl3N2OS
Molar mass359.65 g·mol−1
3D model (JSmol)
Melting point175 to 176 °C (347 to 349 °F)
  • CSc3nc2cc(Cl)c(Oc1cccc(Cl)c1Cl)cc2[nH]3
  • InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19) checkY
  • Key:NQPDXQQQCQDHHW-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat fascioliasis and paragonimiasis.[1] It is very effective for both conditions.[1] Treatment in hospital may be required.[1] It is taken by mouth with typically one or two doses being required.[1]

Side effects are generally few, but can include abdominal pain and headaches.[1] Biliary colic may occur due to dying worms.[2] While no harm has been found with use during pregnancy, triclabendazole has not been studied well in this population.[2] It is a member of the benzimidazole family of medications for worms.[1]

Triclabendazole was approved for medical use in the United States in 2019.[3][4] It is on the World Health Organization's List of Essential Medicines.[5] For human use, it can be obtained from the World Health Organization.[2] It is also used in animals.[6]

  1. ^ a b c d e f World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 94, 96. hdl:10665/44053. ISBN 9789241547659.
  2. ^ a b c Wolfe MM, Lowe RC (2014). "Benzimidazoles". Pocket Guide to GastrointestinaI Drugs. John Wiley & Sons. p. PT173. ISBN 9781118481554. Archived from the original on 20 December 2016.
  3. ^ "Drug Trials Snapshots: Egaten". U.S. Food and Drug Administration (FDA). 13 February 2019.
  4. ^ "Egaten (triclabendazole)" (PDF). FDA. Retrieved 18 February 2019.
  5. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ^ "Triclabendazole". Drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.